Literature DB >> 476593

Ureteral obstruction secondary to metastatic breast carcinoma.

L G Feun, A Drelichman, A Singhakowinta, V K Vaitkevicius.   

Abstract

An uncommon manifestation of breast cancer is ureteral obstruction secondary to metastatic disease. Five patients who recently developed this complication from two to 20 years after the diagnosis of breast cancer are described. Only two of the five patients had urinary symptoms. All of the patients were older, postmenopausal females who had bone metastases and all had responded to previous hormonal manipulation. Bone scanning was useful in detecting unsuspected hydronephrosis in two patients. Retroperitoneal disease appears to be a complication of long standing breast cancer which is usually hormonally dependent. Routine examination of the bone scan for renal asymmetry may aid in the diagnosis, especially in asymptomatic patients.

Entities:  

Mesh:

Year:  1979        PMID: 476593     DOI: 10.1002/1097-0142(197909)44:3<1164::aid-cncr2820440355>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Ureteral involvement by metastatic malignant disease.

Authors:  Jieping Hu; Jun Deng; Ju Guo; Bin Fu
Journal:  Clin Exp Metastasis       Date:  2019-08-24       Impact factor: 5.150

2.  Metastatic disease of the ureter: patterns of tumoral spread and radiologic findings.

Authors:  B Marincek; J R Scheidegger; U E Studer; R Kraft
Journal:  Abdom Imaging       Date:  1993

3.  A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast.

Authors:  M Harris; A Howell; M Chrissohou; R I Swindell; M Hudson; R A Sellwood
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

4.  Ureteral metastasis from a HER2-enriched breast cancer: a rare case report.

Authors:  Jun Zhou; Jian Liu; Aizhai Xiang; Yanna Shan; Jingjing Xiang; Wei Wang; Haidong Cui
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.